Quantcast

Latest Multiple Myeloma Research Consortium Stories

2009-06-01 07:30:00

Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc.

2008-12-09 09:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

2008-11-06 15:00:28

The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma.

2008-10-14 09:00:44

The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

2008-10-13 12:00:41

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID(R) (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

2008-08-25 12:01:19

The Multiple Myeloma Research Consortium has started a Phase I/II clinical trial with the oral immunomodulatory agent pomalidomide in patients who have received at least two prior therapies including treatments with Revlimid and Velcade for injection.

2008-08-22 18:00:43

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection.

2008-08-13 09:01:15

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

2008-07-18 15:00:57

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma.

2008-07-10 09:01:29

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.


Word of the Day
adustion
  • The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
  • In medicine, cauterization.
The word 'adustion' comes from the Latin 'adustio', 'burning'.
Related